Indonesia Energy Provides Update on Operations and Reserves and Planned Drilling During the Remainder of 2025
JAKARTA, INDONESIA AND DANVILLE, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Indonesia Energy Corporation (NYSE American: INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today provided an update on IEC's planned drilling activity for the second half of 2025.
During 2024, IEC scaled back drilling activity at its Kruh Block asset and invested in seismic and other exploration work intended to maximize the prospects for new drilling. With that work now completed, new drilling is expected to commence at Kruh Block in the second half of 2025, as IEC plans to drill at least one new well this year as part of its multi-year program to drill 18 new wells at Kruh Block.
In its recently filed Annual Report on Form 20-F, IEC updated its proved gross reserves at Kruh Block, noting that IEC's proved reserves increased over 60% to approximately 3.3 million barrels as a result of the additional seismic and other work conducted in 2024 and the 5-year contract extension granted in late 2023 by the Indonesian government.
Mr. Frank Ingriselli, IEC's President, commented "We are pleased that our investments in Kruh Block and the 3D seismic work we have now completed resulted in a 60% increase in our proved gross reserves (even without any additional drilling activity). After attending meetings with the technical and operating teams in Jakarta and meetings with the drilling and operating teams in Sumatra, we are finalizing the drilling plans for later this year. With a successful result from our next well, we are hopeful that a further increase in reserves will be forthcoming. We believe our seismic data in hand will make our drilling even more effective and help us maximize the returns from this important asset'
More information regarding IEC's planned drilling activities and reserve details for the Kruh Block and the Citarum Block can be found in IEC's Annual Report on Form 20-F which was filed last month with the Securities and Exchange Commission and is available on IEC's website at: https://ir.indo-energy.com/sec-filings/
About Indonesia Energy Corporation Limited
Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC's principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (195,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.
Cautionary Statement Regarding Forward-Looking Statements
All statements in this press release, and related statements of Indonesia Energy Corporation Limited ('IEC') and its representatives and partners that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Acts'). In particular, the words 'could,' "estimates," "believes," "hopes," "expects," "intends," 'on-track', "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. In this press release, forward-looking statements include, without imitation those related to IEC's future drilling plans at Kruh Block. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of significant risks, uncertainties, and other factors, many of which are outside of the IEC's control, that could cause actual results to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed on April 29, 2025, and other filings with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC's website, www.sec.gov and IEC's website at https://ir.indo-energy.com/sec-filings/. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Company Contact:
Frank C. IngriselliPresident, Indonesia Energy Corporation LimitedFrank.Ingriselli@Indo-Energy.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
Spherix Global Insights' new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent thalassemia patients remain tethered to long-term transfusion support. Transfusions, while providing symptom relief, in turn create logistical barriers and their own clinical challenges. New data from Spherix Global Insights' independent chart audit, Patient Chart Dynamix™: Transfusion Dependent Thalassemia 2025 (US), is based on insight from 81 real-world patient charts submitted by 49 US-based hematologists. These data paint a complex picture of therapeutic inertia, growing anticipation for emerging treatments, and deep-seated frustration with limitations of current treatment options. Most transfusion-dependent beta thalassemia patients follow some regular transfusion schedule. That said, many receive them at relatively extended intervals: often once a month or even less frequently, though a small subset still require more frequent transfusions. This variation in treatment patterns, along with persistent symptoms and unmet needs highlighted in the chart audit, points to a strong opportunity for new therapies to improve care for a broad range of patients. Among surveyed hematologists, mitapivat (Agios) currently holds a slight edge in name recognition over etavopivat (Novo Nordisk). Interestingly, despite this difference in familiarity, physicians identified slightly more patients as potential candidates for etavopivat, hinting at a broader perceived clinical fit once awareness and understanding of the agent catch up. Chart audit data allows users to probe further into specific patient types which physicians perceive as better fits for either agent, as well as those who they do not perceive as candidates. This growing interest in emerging oral therapies reflects a broader desire among hematologists for more accessible, lower-burden treatment options. While most patients are theoretically eligible for curative approaches like gene therapy, the market still favors lower-barrier alternatives. These alternatives include oral therapies that do not require referral to specialized centers or extensive pre-conditioning, and brands with which they are more familiar given other indications such as Reblozyl (Bristol Myers Squibb). Disease-modifying therapies that are easier to prescribe and integrate into routine practice have the promise to significantly improve the lives of patients who would not qualify or want gene therapy. Access barriers compound the issue, with over half of physicians voicing frustration over payer restrictions that make it difficult to initiate optimal care. These challenges highlight a critical need – not just for clinical innovation, but also for strong manufacturer support in navigating reimbursement and expanding access. As the beta thalassemia landscape continues to evolve, hematologists are increasingly looking toward emerging therapies that are easier to prescribe, carry fewer logistical burdens than gene therapy, and offer clear reductions in transfusion dependency. Products like mitapivat and etavopivat are well-positioned to address this gap, assuming familiarity, confidence, and access grow in tandem – but the goal to cure patients of hemoglobinopathies still carries heavy weight, with desire to treat with gene therapy consistently growing. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Utah Valley University Unveils Innovative Autonomous Aircraft Tug 2.0 at Provo Airport
Engineering Students Revolutionize Aircraft Taxiing With Smart, Fuel-Saving Technology UVU airplane tug demonstration 1 UVU airplane tug demonstration 2 Orem, Utah, June 04, 2025 (GLOBE NEWSWIRE) -- Utah Valley University (UVU) has unveiled version 2.0 of its autonomous electric aircraft tug, a cutting-edge student-driven innovation designed to reduce fuel consumption, lower emissions, and enhance airport safety. Recently demonstrated at the Provo Airport, this next-generation tug aims to transform how aircraft move on runways. Aircraft Tug 2.0: What's New? The redesigned prototype features major upgrades, including a hands-free coupling and decoupling system for seamless aircraft attachment, remote-control operation via cellular datalink with a live video feed, and a redesigned drivetrain for improved performance and efficiency. According to Dr. Brett Stone, UVU mechanical engineering professor and former Northrop Grumman design engineer, 'The latest redesign has taken the tug to the next level. Months of brainstorming, testing, and labor have paid off, and it's thrilling to show people how it works.' Solving Aviation's Fuel and Safety Challenges Aircraft traditionally taxi using jet engines, which consume 70-80 gallons of fuel taxiing from the jetway to the runway at airports like Salt Lake City International. In 2019 alone, adopting electric tugs could have saved airlines at SLC International $2.17 million in fuel costs while reducing noise and emissions — equivalent to removing 2,400+ cars from the road annually. 'This year, we built on last year's groundwork to modify, assemble, and test the tug,' said Bradan Penrod, a mechanical engineering student at UVU. 'The attachment mechanism was one of the toughest challenges, requiring precision and problem-solving. As a mechanical engineer, learning the electrical systems was also a steep curve, but working with others made it easier. The hands-on experience working on the tug has definitely prepared me for the workforce.' Beyond environmental benefits, the tug enhances airport worker safety. Unfortunately, tarmac personnel face risks when working with live jet engines, and UVU's autonomous tug provides a safer, fuel-efficient alternative. Industry Recognition and Commercial Potential Launched by Engineering Professors Brett Stone and Matt Jensen and Computer Science Professor George Rudolph, the project was designed to give students hands-on engineering experience. Two different teams of eight mechanical engineering and four computer science students built the prototype over two semesters, backed by $15,000 in grant funding from Rocky Mountain Power Foundation. Their innovation won first place at the ACRP University Design Competition in 2024, securing an additional $3,000 award. The project has since attracted industry attention, with patents pending and discussions about commercial applications. The Future of UVU's Aircraft Tug With further development, UVU aims to scale the tug for larger regional jets like the Embraer and Canadair — and eventually Boeing 737 and Airbus A320 aircraft. Additional applications include autonomous towing for baggage trains and snowplows and flexible operating modes: pilot-controlled, remote-operated, or fully autonomous. 'We are optimistic about its commercial future,' said Professor Stone. 'The technology is proving that student-led innovation can redefine aviation sustainability.' ### Attachments UVU airplane tug demonstration 1 UVU airplane tug demonstration 2 CONTACT: Scott Trotter Utah Valley University 8014196860 in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Over the Counter (OTC) Drugs Market Report 2025: Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts to 2034
Driven by self-medication trends, health-conscious consumers, and innovative formulations, the OTC drugs market thrives on the widespread availability of non-prescription drugs. Key segments include cold remedies and tablets, heavily favored for convenience. The U.S. market alone is expected to expand at a 4.8% CAGR, fueled by strong R&D and self-care trends. Over the Counter (OTC) Drugs Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Over the Counter (OTC) Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Over the Counter (OTC) Drugs Market was valued at USD 180 Billion in 2024, and is projected to reach USD 302.3 Billion by 2034, rising at a CAGR of 5.40%, driven largely by a rising consumer preference for self-medication and increasing demand for accessible healthcare solutions. As consumers become more health-conscious and proactive in managing minor ailments, OTC drugs are quickly emerging as a go-to solution for quick relief and cost-effective treatment options. The widespread availability of OTC products in pharmacies, supermarkets, online platforms, and convenience stores is making it easier for consumers to access essential medications without a prescription. In addition, ongoing advancements in drug formulations, such as fast-dissolving tablets and flavored syrups, are enhancing user convenience and compliance, fueling market growth even further. Regulatory bodies across the globe are also playing a crucial role by ensuring stringent quality checks and guidelines, which boost consumer confidence in using OTC medications for everyday health concerns. As healthcare costs continue to rise, many individuals are opting for OTC options to manage common conditions like pain, colds, digestive issues, and skin irritations without the need for physician visits, thereby contributing to overall market expansion. Furthermore, an aging population seeking easy and affordable solutions for recurring issues like joint pain, digestive discomfort, and sleep disorders is supporting long-term demand for OTC products. The growing trend toward preventive healthcare and wellness supplements is also influencing consumer purchasing behavior, with many people adopting vitamins, minerals, and herbal supplements as part of their daily routines to maintain health and drugs, which do not require a doctor's prescription, are carefully regulated by health authorities to ensure their safety, efficacy, and quality. These medications are available in diverse forms, such as tablets, ointments, sprays, and solutions, offering users convenient options for managing common health issues at home. The market is segmented into various categories, including cold and cough remedies, vitamins and supplements, digestive aids, skin treatments, pain relievers, sleeping aids, and others. Among these, cold and cough remedies generated USD 45.2 billion in 2024, as the rising incidence of respiratory illnesses like colds and flu, particularly during seasonal transitions, drives demand for quick-relief products such as decongestants and cough looking at product formulation, tablets dominated the OTC market with USD 85.9 billion in 2024, as they remain the preferred choice due to precise dosing, convenience, and ease of use for treating conditions such as pain, respiratory issues, and other acute ailments. The consistent launch of new tablet-based OTC products continues to boost their market regional analysis, the U.S. OTC Drugs Market accounted for USD 42.4 billion in 2024 and is anticipated to grow at a 4.8% CAGR through 2034. The country's robust pharmaceutical landscape, significant R&D investments, and rising consumer inclination toward self-care are propelling market growth alongside growing awareness around early treatment and preventive healthcare Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis The companies profiled in this Over the Counter (OTC) Drugs market report include: Abbott Alkem Laboratories Aytu Biopharma (Aytu Consumer Health) Bayer AG Cipla Dr. Reddy's Laboratories GlaxoSmithKline Plc Glenmark Pharmaceuticals Haleon Johnson & Johnson Services Perrigo Company Pfizer Piramal Enterprises Reckitt Benckiser Group Sanofi Sun Pharmaceuticals Teva Pharmaceutical Industries The Blackstone Group (Alinamin Pharmaceutical) Viatris Key Attributes: Report Attribute Details No. of Pages 130 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $180 Billion Forecasted Market Value (USD) by 2034 $302.3 Billion Compound Annual Growth Rate 5.4% Regions Covered Global Key Topics Covered: Chapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing consumer awareness for self-medication and disease management3.2.1.2 High cost of prescription drugs leading to shift towards OTC drugs3.2.1.3 Favorable regulatory support for OTC drug approvals3.2.1.4 Expanding product accessibility3.2.2 Industry pitfalls and challenges3.2.2.1 Concern towards misuse or drug abuse3.2.2.2 Potential side effects and interactions due to medication3.3 Growth potential analysis3.4 Regulatory landscape3.5 Prescription to nonprescription switch list3.6 Future market trends3.7 Porter's analysis3.8 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company matrix analysis4.3 Company market share analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Drug Category, 2021-2034 ($ Mn)5.1 Key trends5.2 Cold and cough remedies5.3 Vitamins and supplements5.4 Digestive and intestinal remedies5.5 Skin treatment5.6 Analgesics5.7 Sleeping aids5.8 Other drug categoriesChapter 6 Market Estimates and Forecast, by Formulation Type, 2021-2034 ($ Mn)6.1 Key trends6.2 Tablets6.3 Liquids6.4 Ointments6.5 SpraysChapter 7 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)7.1 Key trends7.2 Online channels7.3 Offline channels7.3.1 Hospital pharmacies7.3.2 Retail pharmacies7.3.3 Other offline channelsChapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)8.1 Key trends8.2 North America8.2.1 U.S.8.2.2 Canada8.3 Europe8.3.1 Germany8.3.2 UK8.3.3 France8.3.4 Spain8.3.5 Italy8.3.6 Netherlands8.4 Asia Pacific8.4.1 China8.4.2 India8.4.3 Japan8.4.4 Australia8.4.5 South Korea8.5 Latin America8.5.1 Brazil8.5.2 Mexico8.5.3 Argentina8.6 Middle East and Africa8.6.1 South Africa8.6.2 Saudi Arabia8.6.3 UAEChapter 9 Company Profiles9.1 Abbott9.2 Alkem Laboratories9.3 Aytu Biopharma (Aytu Consumer Health)9.4 Bayer AG9.5 Cipla9.6 Dr. Reddy's Laboratories9.7 GlaxoSmithKline Plc9.8 Glenmark Pharmaceuticals9.9 Haleon9.10 Johnson & Johnson Services9.11 Perrigo Company9.12 Pfizer9.13 Piramal Enterprises9.14 Reckitt Benckiser Group9.15 Sanofi9.16 Sun Pharmaceuticals9.17 Teva Pharmaceutical Industries9.18 The Blackstone Group (Alinamin Pharmaceutical)9.19 ViatrisCompanies Featured The companies profiled in this Over the Counter (OTC) Drugs market report include: Abbott Alkem Laboratories Aytu Biopharma (Aytu Consumer Health) Bayer AG Cipla Dr. Reddy's Laboratories GlaxoSmithKline Plc Glenmark Pharmaceuticals Haleon Johnson & Johnson Services Perrigo Company Pfizer Piramal Enterprises Reckitt Benckiser Group Sanofi Sun Pharmaceuticals Teva Pharmaceutical Industries The Blackstone Group (Alinamin Pharmaceutical) Viatris For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Over the Counter (OTC) Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
